The Swiss-French biotech company uses a clinically relevant platform to discover and develop novel medications that treat fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. Their cutting-edge platform combines single-cell RNASeq of patient liver tissues with clinically relevant read-outs to put an end to fibrosis and reverse the course of the disease. By doing so, ALENTIS Therapeutics aims to reduce the number of deaths caused by advanced liver diseases.